Pulmonary embolism (PE) and deep vein thrombosis (DVT) are the most common causes of death from cardiovascular disease after heart attack and stroke. DVT most commonly occurs in the legs but can also occur in the arms, mesenteric, and cerebral veins. PE is the most common cause of sudden death in patients with DVT. The diagnosis of PE and DVT is based on clinical probability, imaging, and laboratory tests. D-dimer testing is used to rule out DVT or PE in patients with low clinical probability. Compression ultrasonography is the main imaging technique for DVT, while multidetector CT angiography is used for PE. Anticoagulation is the main treatment for PE and DVT, with the choice of anticoagulant depending on the patient's risk profile. New oral anticoagulants are being developed and may replace vitamin K antagonists and heparins in many patients. These drugs are prescribed in fixed doses and do not require coagulation monitoring. Prophylaxis for venous thromboembolism is underused in patients at moderate or high risk. Prevention strategies include pharmacological and mechanical methods. The use of anticoagulant drugs for prophylaxis is underused in many hospitals, and there is a need for improved implementation of venous thromboembolism prophylaxis. The main risk factors for PE include age, obesity, smoking, and certain medical conditions. The management of PE and DVT involves risk stratification, anticoagulation, and, in some cases, thrombolysis or embolectomy. The prognosis of PE depends on the patient's risk factors and the severity of the condition. The treatment duration of anticoagulation depends on the patient's risk of recurrence and bleeding. The use of new oral anticoagulants is increasing, and they are being used in many patients. The management of PE and DVT requires a multidisciplinary approach, including clinical assessment, imaging, and anticoagulation. The prevention of PE and DVT is crucial, and the use of anticoagulant drugs for prophylaxis is recommended in high-risk patients. The implementation of venous thromboembolism prophylaxis is important to reduce the risk of PE and DVT. The use of anticoagulant drugs for prophylaxis is underused in many hospitals, and there is a need for improved implementation of venous thromboembolism prophylaxis. The main risk factors for PE include age, obesity, smoking, and certain medical conditions. The management of PE and DVT involves risk stratification, anticoagulation, and, in some cases, thrombolysis or embolectomy. The prognosis of PE depends on the patient's risk factors and the severity of the condition. The treatment duration of anticoagulation depends on the patient's risk of recurrence and bleeding.Pulmonary embolism (PE) and deep vein thrombosis (DVT) are the most common causes of death from cardiovascular disease after heart attack and stroke. DVT most commonly occurs in the legs but can also occur in the arms, mesenteric, and cerebral veins. PE is the most common cause of sudden death in patients with DVT. The diagnosis of PE and DVT is based on clinical probability, imaging, and laboratory tests. D-dimer testing is used to rule out DVT or PE in patients with low clinical probability. Compression ultrasonography is the main imaging technique for DVT, while multidetector CT angiography is used for PE. Anticoagulation is the main treatment for PE and DVT, with the choice of anticoagulant depending on the patient's risk profile. New oral anticoagulants are being developed and may replace vitamin K antagonists and heparins in many patients. These drugs are prescribed in fixed doses and do not require coagulation monitoring. Prophylaxis for venous thromboembolism is underused in patients at moderate or high risk. Prevention strategies include pharmacological and mechanical methods. The use of anticoagulant drugs for prophylaxis is underused in many hospitals, and there is a need for improved implementation of venous thromboembolism prophylaxis. The main risk factors for PE include age, obesity, smoking, and certain medical conditions. The management of PE and DVT involves risk stratification, anticoagulation, and, in some cases, thrombolysis or embolectomy. The prognosis of PE depends on the patient's risk factors and the severity of the condition. The treatment duration of anticoagulation depends on the patient's risk of recurrence and bleeding. The use of new oral anticoagulants is increasing, and they are being used in many patients. The management of PE and DVT requires a multidisciplinary approach, including clinical assessment, imaging, and anticoagulation. The prevention of PE and DVT is crucial, and the use of anticoagulant drugs for prophylaxis is recommended in high-risk patients. The implementation of venous thromboembolism prophylaxis is important to reduce the risk of PE and DVT. The use of anticoagulant drugs for prophylaxis is underused in many hospitals, and there is a need for improved implementation of venous thromboembolism prophylaxis. The main risk factors for PE include age, obesity, smoking, and certain medical conditions. The management of PE and DVT involves risk stratification, anticoagulation, and, in some cases, thrombolysis or embolectomy. The prognosis of PE depends on the patient's risk factors and the severity of the condition. The treatment duration of anticoagulation depends on the patient's risk of recurrence and bleeding.